Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Azvudine
The First People's Hospital of Lianyungang
COVID-19
1 trial -
Babaodan oral capsule
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
Basiliximab
The First People's Hospital of Lianyungang
Safety and Efficacy
1 trial -
Basiliximab,
The First People's Hospital of Lianyungang
Beta-Thalassemia Major
1 trial -
Berberine
The First People's Hospital of Lianyungang
Diabetes Mellitus
1 trial -
Blinatumomab
The First People's Hospital of Lianyungang
Acute B-cell Lymphoblastic Leukemia
1 trial -
Budesonide 200 microgram/Puff, HFA MDI
The First People's Hospital of Lianyungang
Asthma
1 trial -
Bupivacaine Hydrochloride
The First People's Hospital of Lianyungang
Pulmonary Nodule
1 trial -
Busulfan
The First People's Hospital of Lianyungang
Thalassemia Major
1 trial -
Butylphthalide
The First People's Hospital of Lianyungang
Focal Epilepsy
1 trial -
CFNB group
The First People's Hospital of Lianyungang
Postoperative Pain
1 trial -
CSII
The First People's Hospital of Lianyungang
Diabetes Mellitus, Type 2
1 trial -
CTB group
The First People's Hospital of Lianyungang
Post-operative Pain
1 trial -
Calcitriol
The First People's Hospital of Lianyungang
Glomerulonephritis
1 trial -
Chemoembolization and Response-Dependent Resection
The First People's Hospital of Lianyungang
Resectable Hepatocellular Carcinoma Beyond Milan Criteria
1 trial -
Cholecalciferol
The First People's Hospital of Lianyungang
Peritoneal Dialysis-associated Peritonitis
1 trial -
Cilostazol
The First People's Hospital of Lianyungang
Cerebral Small Vessel Disease
1 trial -
Cinobufacini injection
The First People's Hospital of Lianyungang
Liver Cancer
1 trial -
Ciprofol
The First People's Hospital of Lianyungang
ECMO Treatment
1 trial -
Ciprofol
The First People's Hospital of Lianyungang
Postoperative Delirium (POD)
1 trial -
Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses
The First People's Hospital of Lianyungang
HER2 Positive Breast Cancer
1 trial -
Combination of antiplatelet drugs and anticoagulants for at least one month
The First People's Hospital of Lianyungang
Acute Myocardial Infarction
1 trial -
Dabigatran Etexilate
The First People's Hospital of Lianyungang
Atrial Fibrillation
1 trial -
Dapagliflozin 10 MG
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources